Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2014 Earnings Presentation
19 slides from Vita Life Sciences's earnings presentation, Mar 31, 2016
Slide 1: Results Presentation – Half Year ended 30 June 2014
Vita Life Sciences Ltd Results Presentation Half Year ended 30 June 2014 herbsofgold al.ife Dedicated to your health Enriching Lives .Since 1947 18 August 2014 \ 5
Slide 2: Company overview
Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, packaging, sales and distribution of vitamins and supplements 800 registered sku of vitamins and supplements sold in 8 countries in the Asia Pacific region 2 major brands 1. VitaHealth: products s
Slide 3: Half year 2014 highlights
1 Half year 2014 Group revenue increased by 3.8% to $17.7m 2 Half year 2014 Group EBIT increased by 30.3% to $3.3m 3 Continued strong operating cashflow to EBITDA conversion of 101% Half year 2014 Interim Dividend increase by 0.5 cents per share to 4 1.5 cents per share Other Asia revenue continued
Slide 4: Revenue, EBIT and DPS
Revenue EBIT DPS (A$m) (A$m) (cps) 20 4 2 16 3 12 2 1 8 1 4 0 0 0 2011 2012 2013 2014 2011 2012 2013 2014 2011 2012 2013 2014 First Half Second Half First Half Second Half First Half Second Half 3
Slide 5: Half year revenue by geography
2011 half year revenue by geography 2014 half year revenue by geography (1) (1) Other Asia Other Asia 7% 15% Singapore 16% Australia Singapore 37% Australia 15% 45% Malaysia 37% Malaysia 37% Total revenue: $11.3m Total revenue: $17.7m Thailand, Vietnam, China and Indonesia OTC businesses and Multi-L
Slide 6: Vita Life Sciences strategy
Vita Life Sciences strategy has been: Establish sustainable platform for revenue growth through expanding operations into new 50 million plus population markets in Asia Drive profit growth through continued investment in new product development The strategy to focus on profitable growth is b
Slide 7: Australia segment results
Revenue (A$m) 8 Sales revenue of $6.6m, a decrease of 5.1% against half year 2013 6 Sales were impacted by: 4 Continued focus on substituting 2 commoditised products with unique formulation premium ingredient products 0 2011 2012 2013 2014 Competition in a mature market First Half Second Hal
Slide 8: Malaysia segment results
Revenue (A$m) 6 Sales revenue of $6.0m increased 15.6% 4 against half year 2013 Strong momentum in the Vita Health 2 brand being driven by Vita Health being recognised as one of Malaysia’s leading OTC brands 0 2011 2012 2013 2014 First Half Second Half EBIT of $1.3m increased 28.8% against EBI
Slide 9: Singapore segment results
Revenue (A$m) 3 Sales revenue of $2.6m,a decrease of 5.9% against half year 2013 Sales growth has averaged 12.2% per 2 annum over the 3 years to half year 2014 with the decline in half year 2014 revenue 1 attributable to: Cycling of very strong growth in half year 0 2013 of 29.4% 2011 2012 201
Slide 10: Other Asia segment results
Revenue (A$m) 3 Sales revenue of $2.6m increased 16.3% against half year 2013 Vietnam and China continued double digit revenue growth which was partially offset 2 by a decline in revenue in Thailand due to the prevailing political situation Collectively, Other Asia continued to move towards br
Slide 11: Interim dividend declared of 1.5 cents per share
Interim dividend declared of 1.5 cents per share for HY14 (1.0 cent HY13) Interim dividend will be unfranked & contains no Foreign Conduit Income Dividend reinvestment plan is currently suspended Gross operating cashflow to EBITDA DPS (cps) 125% 2.0 100% 1.5 75% 1.0 50% 0.5 25% 0% 0.0 2011 201
Slide 12: Australian CEO appointment and Malaysian premises
The Group’s Australian business has reached the stage in its development where it requires the appointment of an experienced and skilled CEO Following an extensive executive search, the Board is please to announce the appointment of Mr Andrew O’Keefe as Chief Executive Officer – Australia Mr O
Slide 13: Trading update and guidance
Trading update Directors full year revenue guidance is $37m to $38m Directors full year guidance for EBIT is $6.5m to $7.0m 12
Slide 14: Appendix
Appendix
Slide 15: Half year ended 30 June
Half year ended 30 June 2014 2013 Change $m $m % Revenue 17.74 17.08 4% EBITDA 3.36 2.63 28% EBIT 3.31 2.54 30% Profit before tax 3.34 2.54 31% Profit after tax 4.66 2.15 118% EPS (Diluted – cents) 8.20 3.79 116% Dividend (cents / share) 1.50 1.00 50% 14
Slide 16: Balance Sheet
Balance Sheet 2014 2013 $m $m Current assets 21.16 20.49 Non-current assets 3.19 1.52 Total assets 24.35 22.01 Current liabilities (5.20) (5.68) Non-current liabilities (0.07) (0.06) Total Liabilities (5.27) (5.74) Net Assets 19.08 16.27 15
Slide 17: Cash Flow
Cash Flow 2014 2013 $m $m Receipts from customers 19.21 18.72 Payments to suppliers and employees (15.81) (16.01) Gross operating cash flow 3.40 2.71 EBITDA 3.36 2.63 Gross operating cash flow / EBITDA 101% 103% Net interest received / (paid) 0.02 (0.01) Income tax paid (0.45) (0.17) Operating cash
Slide 18: Contact Details
Contact Details Telephone: +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 17
Slide 19: Disclaimer
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis